ADC THERAPEUTICS SA (ADCT)
CH0499880968 - Common Stock
Overall ADCT gets a fundamental rating of 2 out of 10. We evaluated ADCT against 610 industry peers in the Biotechnology industry. ADCT may be in some trouble as it scores bad on both profitability and health. ADCT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ADCT has reported negative net income.
ADCT had a negative operating cash flow in the past year.
In the past 5 years ADCT always reported negative net income.
ADCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ADCT's Return On Assets of -38.23% is fine compared to the rest of the industry. ADCT outperforms 63.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.23% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-38.2%
ROA(5y)-56.19%
ROE(3y)-129.18%
ROE(5y)-117.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 98.36%, ADCT belongs to the best of the industry, outperforming 98.01% of the companies in the same industry.
ADCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADCT has more shares outstanding
Compared to 5 years ago, ADCT has more shares outstanding
ADCT has a worse debt/assets ratio than last year.
2.2 Solvency
ADCT has an Altman-Z score of -3.05. This is a bad value and indicates that ADCT is not financially healthy and even has some risk of bankruptcy.
ADCT has a Altman-Z score of -3.05. This is comparable to the rest of the industry: ADCT outperforms 44.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.05 |
ROIC/WACCN/A
WACC6.7%
2.3 Liquidity
A Current Ratio of 4.80 indicates that ADCT has no problem at all paying its short term obligations.
ADCT has a Current ratio (4.80) which is in line with its industry peers.
ADCT has a Quick Ratio of 4.51. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.51, ADCT perfoms like the industry average, outperforming 48.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.8 | ||
| Quick Ratio | 4.51 |
3. Growth
3.1 Past
ADCT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.85%.
The Revenue for ADCT has decreased by -21.99% in the past year. This is quite bad
The Revenue has been growing by 159.03% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1.85%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q10.77%
Revenue 1Y (TTM)-21.99%
Revenue growth 3Y350.22%
Revenue growth 5Y159.03%
Revenue growth Q2Q-81.01%
3.2 Future
ADCT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.67% yearly.
ADCT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.99% yearly.
EPS Next Y-25.87%
EPS Next 2Y-2.17%
EPS Next 3Y5.67%
EPS Next 5YN/A
Revenue Next Year-65.48%
Revenue Next 2Y-35.87%
Revenue Next 3Y-21.12%
Revenue Next 5Y4.99%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
ADCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.17%
EPS Next 3Y5.67%
5. Dividend
5.1 Amount
No dividends for ADCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADC THERAPEUTICS SA
NYSE:ADCT (12/8/2023, 7:04:00 PM)
1.02
-0.05 (-4.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap82.25M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.23% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.36% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.8 | ||
| Quick Ratio | 4.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-1.85%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-25.87%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-21.99%
Revenue growth 3Y350.22%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y